Insmed announced positive Phase 2b trial results for its pulmonary arterial hypertension drug, TPIP, meeting all endpoints and exceeding Wall Street expectations. The company also priced a public offering of shares at $96.00 per share, aiming to raise $750 million. Analyst Kelly Shi maintained a Buy rating, citing confidence in TPIP's potential. The stock surged significantly following the news.